Once‐weekly (70 mg/m(2)) vs twice‐weekly (56 mg/m(2)) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials

Combination of carfilzomib with dexamethasone (Kd) is approved for use in relapsed and/or refractory multiple myeloma (RRMM), with carfilzomib administered twice weekly at 56 mg/m(2) (Kd56 BIW) or once weekly at 70 mg/m(2) (Kd70 QW). Post hoc cross‐trial comparisons were performed to compare efficac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Moreau, Philippe, Stewart, Keith A., Dimopoulos, Meletios, Siegel, David, Facon, Thierry, Berenson, James, Raje, Noopur, Berdeja, Jesus G., Orlowski, Robert Z., Yang, Hui, Ma, Haijun, Klippel, Zandra, Zahlten‐Kumeli, Anita, Mezzi, Khalid, Iskander, Karim, Mateos, Maria‐Victoria
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7196059/
https://ncbi.nlm.nih.gov/pubmed/32108443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2945
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados